Therapeutic relevance of the allosteric modulation of the 5-HT transporter

Current Signal Transduction Therapy

Volumn 4, Issue 2, 2009, Pages 82-87

  Mnie Filali, Ouissame ^a   El Mansari, Mustafa ^b   Sánchez, Connie ^c   Haddjeri, Naser ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

^c H LUNDBECK A S   (Denmark)

Author keywords

Allosteric modulation; Conformational modification; Enantiomers; Escitalopram; Protein kinase C; R citalopram; Serotonin transporter

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; SEROTONIN TRANSPORTER;

ALLOSTERISM; CELLULAR DISTRIBUTION; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG MECHANISM; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; REGULATORY MECHANISM; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70350364896     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436209788167538     Document Type: Review

References (72)

1. Schwartz TW, Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 2006; 26: 107-28.
2. Perutz MF, Wilkinson AJ, Paoli M, Dodson GG. The stereochemical mechanism of the cooperative effects in hemoglobin revisited. Annu Rev Biophys Biomol Struct 1998; 27: 1-34.
3. Voet D, Voet JG. In: DeBoeck Université Ed, Biochimie 1998; 123-5.
4. Bellelli A, Brunori M, Miele AE, Panetta G, Vallone B. The allosteric properties of hemoglobin: insights from natural and site directed mutants. Curr Protein Pept Sci 2006; 7: 17-45.
5. Soudijn W, Van wijngaarden I, Ijzerman AP. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today 2004; 9: 752-8.
6. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10: 19-23.
7. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996; 277: 861-71.
8. Baumann P, Eap CB. Enantiomeric antidepressant drugs should be considered on individual merit. Hum Psychopharmacol 2001; 16: 85-92.
9. Sánchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003; 167: 353-62.
10. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-6.
11. Hyttel J, Bogeso KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram residues in the (S)- (+) -enantiomer. J Neural Transm Gen Sect 1992; 88: 157-60.
12. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149-55.
13. Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001; 88: 282-6.
14. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102.
15. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17: 343-62.
16. Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45: 167-73.
17. Cremers TIFH,Westerink BHC. Pharmacological difference between escitalopram and citalopram. Int J Psychiatr Clin Prac 2003; 7: 306.
18. Sánchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004; 77: 391-8.
19. Stórustovu S, Sánchez C, Porzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004; 142: 172-80.
20. Sánchez C. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 2003; 464: 155-8.
21. Sánchez C, Gruca P, Bien E, Papp M. R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 2003; 75: 903-7.
22. Fish EW, Faccidomo S, Gupta S, Miczek KA. Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther 2004; 308: 474-80.
23. Bien E, Gruca P, Papp MR. Citalopram attenuates the anxiolytic-like activity of escitalopram in two animal models. Behav Pharmacol 2003; 14: S31.
24. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732-9.
25. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
26. Mnie-Filali O, El Mansari M, Espana A, Sánchez C, Haddjeri N. Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neurosci Lett 2006; 395: 23-7.
27. El Mansari M, Sánchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology. 2005; 30: 1269-77.
28. Sánchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003; 14: 465-70.
29. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
30. Faure C, Mnie-Filali O, Haddjeri N. Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev Neurother 2006; 6: 235-45.
31. Jayatissa MN, Bisgaard C, Tingstrom A, Papp M, Wiborg O. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006; 31: 2395-404.
32. Mnie-Filali O, Faure C, El Mansari M, et al. R-citalopram prevents the neuronal adaptive changes induced by escitalopram. NeuroReport 2007; 18: 1553-56.
33. Chen F, Larsen MB, Neubauer HA, Sánchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 2005; 92: 21-8.
34. Czachura JF, Rasmussen K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 266-75.
35. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15: 193-8.
36. Plenge P, Mellerup ET. Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes. Eur J Pharmacol 1985; 119: 1-8.
37. Wennogle LP, Meyerson LR. Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranes. Life Sci 1985; 36: 1541-50.
38. Plenge P, Mellerup ET, Laursen H. Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 1991; 206: 243-50.
39. Plenge P, Gether U, Rasmussen SG. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. Eur J Pharmacol 2007; 567: 1-9.
40. Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 2007; 10: 31-40.
41. Neubauer HA, Hansen CG, Wiborg O. Dissection of an allosteric mechanism on the serotonin transporter: a cross-species study. Mol Pharmacol 2006; 69: 1242-50.
42. Nelson PJ, Rudnick G. Coupling between platelet 5-hydroxytryptamine and potassium transport. J Biol Chem 1979; 254: 10084-9.
43. Talvenheimo J, Fishkes H, Nelson PJ, Rudnick G. The serotonin transporter-imipramine "receptor". J Biol Chem 1983; 258: 6115-9.
44. Zhang YW, Rudnick G. The cytoplasmic substrate permeation pathway of serotonin transporter. J Biol Chem 2006; 281: 36213-20.
45. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature 2005; 437: 215-23.
46. Cao Y, Li M, Mager S, Lester HA. Amino acid residues that control pH modulation of transport-associated current in mammalian serotonin transporters. J Neurosci 1998; 18: 7739-49.
47. Sato Y, Zhang YW, Androutsellis-Theotokis A, Rudnick G. Analysis of transmembrane domain 2 of rat serotonin transporter by cysteine scanning mutagenesis. J Biol Chem 2004; 279: 22926-33.
48. Jorgensen AM, Tagmose L, Jorgensen AM, et al. Homology Modeling of the Serotonin Transporter: Insights into the Primary Escitalopram binding Site. ChemMedChem 2007; 2: 815-26.
49. Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, Javitch JA. Probing conformational changes in neurotransmitter transporters: a structural context. Eur J Pharmacol 2003; 479: 3-12.
50. Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem 2001; 276: 3805-10.
51. Sorkina T, Doolen S, Galperin E, Zahniser NR, Sorkin A. Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J Biol Chem 2003; 278: 28274-83.
52. Torres GE, Carneiro A, Seamans K, et al. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 2003; 278: 2731-9.
53. Scholze P, Freissmuth M, Sitte HH. Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1. J Biol Chem 2002; 277: 43682-90.
54. Veenhoff LM, Heuberger EH, Poolman B. Quaternary structure and function of transport proteins. Trends Biochem Sci 2002; 27: 242-9.
55. Cuppoletti J, Goldinger J, Kang B, Jo I, Berenski C, Jung CY. Anion carrier in the human erythrocyte exists as a dimer. J Biol Chem 1985; 260: 15714-7.
56. Macara IG, Cantley LC. Interactions between transport inhibitors at the anion binding sites of the band 3 dimer. Biochemistry 1981; 20: 5095-105.
57. Chang AS, Starnes DM, Chang SM. Possible existence of quaternary structure in the high-affinity serotonin transport complex. Biochem Biophys Res Commun 1998; 249: 416-21.
58. Horschitz S, Hummerich R, Schloss P. Functional coupling of serotonin and noradrenaline transporters. J Neurochem 2003; 86: 958-65.
59. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003; 4: 181-91.
60. Sitte HH, Farhan H, Javitch JA. Sodium-Dependent Neurotransmitter Transporters oligomerization as a Determinant of Transporter Function and Trafficking. Mol Interv 2004; 4: 38-47.
61. Farhan H, Freissmuth M, Sitte HH. Oligomerization of neurotransmitter transporters: a ticket from the endoplasmic reticulum to the plasma membrane. Handb Exp Pharmacol 2006; 175: 233-49.
62. Blakely RD, Bauman AL. Biogenic amine transporters: regulation in flux. Curr Opin Neurobiol 2000; 10: 328-36.
63. Robinson MB. Regulated trafficking of neurotransmitter transporters: common notes but different melodies. J Neurochem 2002; 80: 1-11.
64. Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci 1997; 17: 45-57.
65. Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem 1998; 273: 2458-66.
66. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999; 285: 763-6.
67. Jayanthi LD, Annamalai B, Samuvel DJ, Gether U, Ramamoorthy S. Phosphorylation of the norepinephrine transporter at threonine 258 and serine 259 is linked to protein kinase C-mediated transporter internalization. J Biol Chem 2006; 281: 23326-40.
68. Vaughan RA, Huff RA, Uhl GR, Kuhar MJ. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 1997; 272: 15541-6.
69. Zhang L, Coffey LL, Reith ME. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem Pharmacol 1997; 53: 677-88.
70. Daniels GM, Amara SG. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem 1999; 274: 35794-801.
71. Chi L, Reith ME. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Pharmacol Exp Ther 2003; 307: 729-36.
72. Iceta R, Mesonero JE, Alcalde AI. Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci 2007; 80: 1517-24.